Entries by Thomas Gabrielczyk

BioIVT | Human AB Serum – Plasma-derived

Serum-supplemented cell culture media remains the gold standard for obtaining near in vivo conditions. That’s why we have expanded our product line to include GMP-grade Human AB Serum.

How the German capital region supports founders

The Berlin-Brandenburg capital region is one of the leading life science ­regions in Europe and a lot is being done to keep it that way: with a wide variety of space offerings and support programs for founders and start-ups.

13th European Biotechnology Guide 2023

The 13th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. In addition to the detailed portraits on approx. 188 colored pages, the guide features a report about sustainibility and the biologisation of industrial production. Readers will discover many success stories and current trends in the European biotech industry.

Biontech leaves; what does Germany do?

In soccer, such a transfer would raise tempers: A superstar leaves his team because he no longer trusts it to succeed. A warning sign, a headline event, fodder for weeks of debate in the media. Something similar has just happened to the biotech industry, but things remain strangely quiet in the fan block of Germany’s top research – whispers at best, just whispers, but no outcry anywhere.

European VCs join US$105m financing of US Mediar Thx

Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.